Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), sucrose octasulfate or sucralfate and hyaluronic acid for the treatment, pre-emptive treatment or prophylaxis of ulcers, wounds and other injuries to the skin or membranes of the body. Other aspects of the invention are methods of treatment or prevention using the compositions described, as well as an application device for use in the methods provided.
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
Type:
Grant
Filed:
October 6, 2022
Date of Patent:
November 14, 2023
Assignee:
GENMAB A/S
Inventors:
David Satijn, Patrick Engelberts, Kristel Kemper, Esther C. W. Breij, Simone Oostindie, Farshid Alemdehy
Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.
Type:
Grant
Filed:
May 5, 2022
Date of Patent:
November 7, 2023
Assignee:
CytoKi Pharma ApS
Inventors:
Kristian Sass-Ørum, Rasmus Jørgensen, Sebastian Beck Jørgensen, Henning Thøgersen, Thomas Hoeg-Jensen, Michael Paolo Bastner Sandrini
Abstract: The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
October 31, 2023
Assignee:
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
Inventors:
Philipp Beckhove, Michael Boutros, Nisit Khandelwal, Marco Breinig
Abstract: This disclosure concerns production of product peptides with a target amino acid sequence by proteolysis of a recombinant polypeptide comprising specific protease recognition sites or chemical cleavage sequences. In some embodiments, the product peptide is released from repeating peptide units in the recombinant polypeptide by removal of intervening amino acid sequences by proteolysis by proteases that recognize sites within the intervening amino acid sequences and a carboxypeptidase, aminopeptidase, and/or further protease.
Abstract: The disclosure concerns a method of treating complications of acute or chronic hyperglycemia and/or diet-induced obesity comprising: (i) determining whether a patient suffers from complications related to acute or chronic hyperglycemia and/or diet induced obesity, and if so, (ii) administering to the patient in need thereof a selective inhibitor of soluble TNF-? but not transmembrane TNF-?. For purposes herein, complications of acute or chronic hyperglycemia and/or diet-induced obesity include: diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, and chronic intestinal inflammation.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
October 24, 2023
Assignees:
INmune Bio Inc, EMORY UNIVERSITY
Inventors:
Maria Elizabeth De Souza Rodrigues, Maria de Lourdes Gamez Tansey, Christopher J. Barnum, Raymond J. Tesi, Dean P. Jones, Douglas I. Walker
Abstract: Disclosed herein are embodiments of a functionalized microbubble designed for treating and/or preventing vascular obstructions, including microvascular obstructions. The functionalized microbubble embodiments comprise a microbubble that can be activated upon exposure to ultrasound and further that has a lipid-based shell that is attached to an exteriorly-attached therapeutically active agent, such as a thrombolytic agent. Also disclosed herein are embodiments of a method for making and using the functionalized microbubble embodiments.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
October 24, 2023
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, UPMC
Inventors:
John J. Pacella, Xucai Chen, Francois Tchi Ho Yu, Thiruganesh Ramasamy, Stephen D'Auria
Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
October 17, 2023
Assignee:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventors:
Andrew F. Stewart, Courtney Ackeifi, Peng Wang, Bob Devita
Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
Type:
Grant
Filed:
January 12, 2022
Date of Patent:
October 10, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Patrick James Knerr, Brian Finan, Richard Dimarchi
Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), in which the peptide is in a complex with an MHC molecule.
Type:
Grant
Filed:
June 29, 2022
Date of Patent:
October 10, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
October 10, 2023
Assignee:
Janssen Sciences Ireland Unlimited Company
Inventors:
Yue-Mei Zhang, Raul Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Type:
Grant
Filed:
August 27, 2020
Date of Patent:
October 3, 2023
Assignees:
Merck Sharp & Dohme LLC, Ambrx, Inc.
Inventors:
Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
September 26, 2023
Assignee:
Seagen Inc.
Inventors:
Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
Abstract: Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with a competitive inhibitor of a glucose transporter, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo.
Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
September 5, 2023
Assignee:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventors:
Andrew F. Stewart, Courtney Ackeifi, Peng Wang, Bob Devita
Abstract: Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.
Type:
Grant
Filed:
April 5, 2021
Date of Patent:
July 25, 2023
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Jesper Gromada, Haruka Okamoto, Stephen Jaspers, Joyce Harp